Ibrutinib resistance in CLL and exploration of alternative therapies

Lynn Wang, MD, PhD
Professor of Pathology
Director, Laboratory of Lymphoma Translational Pathology
University of Chicago

Educational Objectives
At the conclusion of this activity, the learner should better be able to:
1. Understand B-cell receptor signaling in chronic lymphocytic leukemia
2. Summarize mechanisms of ibrutinib resistance
3. Identify strategies to overcome ibrutinib resistance

Accreditation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Credit Designation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships:
The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose:

Nothing to disclose